BioNTech Price Target Maintained With a $171.00/Share by Canaccord Genuity
BioNTech Is Maintained at Buy by Canaccord Genuity
Morgan Stanley Keeps Their Buy Rating on BioNTech SE (BNTX)
HC Wainwright & Co. Reiterates Buy on BioNTech, Maintains $150 Price Target
BioNTech Analyst Ratings
BioNTech's Strategic Acquisition of Biotheus Bolsters Oncology Portfolio and Justifies Buy Rating
Goldman Sachs Maintains BioNTech(BNTX.US) With Buy Rating, Maintains Target Price $137
Goldman Sachs Reaffirms Their Buy Rating on BioNTech SE (BNTX)
J.P. Morgan Maintains BioNTech(BNTX.US) With Hold Rating, Maintains Target Price $124
Analysts Offer Insights on Healthcare Companies: BioNTech SE (BNTX) and Idexx Laboratories (IDXX)
BioNTech Is Maintained at Buy by Canaccord Genuity
BioNTech Price Target Maintained With a $171.00/Share by Canaccord Genuity
BioNTech Analyst Ratings
Goldman Sachs Maintains BioNTech(BNTX.US) With Buy Rating, Maintains Target Price $137
Analysts Are Bullish on Top Healthcare Stocks: Voyager Therapeutics (VYGR), BioNTech SE (BNTX)
CCORF Maintains BioNTech(BNTX.US) With Buy Rating, Maintains Target Price $171
Strategic Acquisition and Oncology Focus Justify BioNTech's Buy Rating
Leerink Partners Maintains BioNTech(BNTX.US) With Buy Rating, Announces Target Price $121
Deutsche Bank Maintains BioNTech(BNTX.US) With Buy Rating, Maintains Target Price $150
Deutsche Bank Reaffirms Their Buy Rating on BioNTech SE (BNTX)